-
Mashup Score: 8ASCO Plenary Series Program - 2 year(s) ago
Learn more about the faculty and program for the January Plenary Series session.
Source: ASCOCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsSebastian BauerDepartment of Medical Oncology and Sarcoma Center/West German Cancer Center, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany; Sebastian Bauer, Robin Lewis Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Raymond Zalcberg, Yoon-Koo Kang,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Very honored to moderate the January #ASCOPlenarySeries session and be joined with amazing speakers @seppobauer @breelynwilkyMD @ChristianRolfo Will highlight the role of #ctDNA in predicting tx efficacy in #GIST #. @3 PM today. Abst: https://t.co/L3CGCPLK9k @OncoAlert #GI23 https://t.co/CS21GfS22e
-
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsSebastian BauerDepartment of Medical Oncology and Sarcoma Center/West German Cancer Center, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany; Sebastian Bauer, Robin Lewis Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Raymond Zalcberg, Yoon-Koo Kang,…
Source: meetings.asco.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
‼️ January #ASCOPlenarySeries session to highlight the role of #ctDNA in predicting tx efficacy in #GIST, other tumors 📅 Live presentation 1/24 @ 3 PM ET Panelists: @SalemGIOncDoc @seppobauer @breelynwilkyMD @ChristianRolfo Abstract: https://t.co/mbyk3SjpIt @OncoAlert #GI23 https://t.co/yDjpoNCyWZ
-
-
Mashup Score: 0
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This month's @NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the #NCCNGuidelines for #GIST: https://t.co/Ev3I2X896F #GastrointestinalStromalTumors #GICSM Earn free #CME #CNE #CPE https://t.co/GmrkzIQloy
-
-
Mashup Score: 0Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine - 3 year(s) ago
Section:The treatment of advanced GI stromal tumor (GIST) has evolved greatly over the past two decades since the introduction of imatinib to treat this disease. The revolution in the treatment of this disease began with the identification of the oncogenic driver c-KIT and the subsequent identification of a series of KIT inhibitors, which have literally transformed this disease. Today, we have…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #JCO #Editorial: Ripretinib and the Failure to Advance #GastrointestinalStromalTumor Therapy in the Age of #PrecisionMedicine. #GIST #scmsm @DrGarySchwartz https://t.co/Gdx9lOrglf https://t.co/5Nf7tJGt2e
-
-
Mashup Score: 2
PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 INTRIGUE Trial: Ipretinib not superior to sunitinib but demonstrates longest median progression free survival ever in advanced #GastrointestinalStromalTumor ➡️ https://t.co/aUNdvXaQcH #GIST #scmsm @seppobauer https://t.co/pPfph6A8Lr
-
-
Mashup Score: 0JNCCN 360 - BiomarkerNTRK - Frequency of NTRK Fusions in Gastrointestinal Stromal Tumors - 3 year(s) ago
By: Vanessa A. Carter, BS Posted: Tuesday, July 26, 2022 Sang Joon Shin, MD, of Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, and colleagues examined the TRK fusion status of patients with gastrointestinal stromal tumors who did not harbor KIT/platelet-derived growth factor receptor alpha…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read about the Frequency of #NTRK Fusions in #GastrointestinalStromalTumors on #JNCCN360: https://t.co/gNMy5OVhPS #GIST #GISM https://t.co/Tgp9lOqvco
-
-
Mashup Score: 0Ripretinib Exhibits Better Tolerability Profile Vs Sunitinib in Advanced GIST Tumors - 3 year(s) ago
An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ripretinib Exhibits Better Tolerability Profile Vs Sunitinib in Advanced #GIST #Tumors #oncology #nursing Link: https://t.co/rOceRlhlzp https://t.co/J7nEg5wfQV
-
-
Mashup Score: 0MOZ and Menin–MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor - 3 year(s) ago
Dependency screening in gastrointestinal stromal tumor identified MOZ and Menin–MLL complexes as complementary chromatin regulators and therapeutic vulnerabilities that control oncogenic transcriptional programs.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the July issue: MOZ and Menin-MLL Complexes are Complementary Regulators of Chromatin Association and Transcriptional Output in #Gastrointestinal Stromal Tumor, by @SarcomaLab, @Armstrong_dfci et al. https://t.co/zhUjAGw48E @DanaFarber #GIST https://t.co/a7GH2Tiuef
-
-
Mashup Score: 0Mark Cuban Pharmacy Offers Imatinib at a Fraction of the Cost - 3 year(s) ago
Mark Cuban has launched a discount pharmacy offering generic drugs at a substantially lower cost than current retail pricing, and currently has several cancer drugs in the formulary.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Billionaire entrepreneur Mark Cuban is offering generic imatinib at a substantially lower cost than current retail pricing. #CML #ALL #GIST https://t.co/gguso4R1NY
-
Don't miss the #ASCOPlenarySeries TODAY @ 3 PM ET! The session will highlight the use of #ctDNA in predicting tx efficacy in #GIST Presenter: @seppobauer Panelists: @SalemGIOncDoc @breelynwilkyMD @ChristianRolfo Details ➡️ https://t.co/cTVUuSw5T3 #gi23 #sarcoma @OncoAlert https://t.co/hVj03GoHV2